Yangtao Wu

Title: Yangtao Wu: Innovator in Hepatitis B Research

Introduction

Yangtao Wu is a prominent inventor based in Xiamen, China. He has made significant contributions to the field of medical research, particularly in the development of antibodies for the treatment of hepatitis B virus (HBV) infections. His innovative work has the potential to improve the lives of many individuals affected by this disease.

Latest Patents

Yangtao Wu holds a patent for an "Anti-hepatitis B virus antibody and uses thereof." This patent discloses antibodies to the anti-hepatitis B surface antigen (HBsAg), especially humanized antibodies. The patent details nucleic acid molecules encoding these antibodies, methods for preparing them, and pharmaceutical compositions containing them. The antibodies exhibit higher affinity for HBsAg at neutral pH compared to acidic pH, significantly enhancing virus clearance efficiency and prolonging the virus inhibition time. These antibodies and their compositions can be utilized for preventing and treating HBV infections or related diseases, neutralizing HBV virulence, reducing serum levels of HBV DNA and HBsAg, and activating the humoral immune response in chronic HBV patients.

Career Highlights

Yangtao Wu has worked at Xiamen University, where he has contributed to various research projects. He is also associated with Yang Sheng Tang Company Limited, where he has furthered his research in the field of hepatitis B. His work has garnered attention for its potential impact on public health.

Collaborations

Yangtao Wu has collaborated with notable colleagues, including Wenxin Luo and Can Wen. These collaborations have enriched his research and contributed to advancements in the understanding and treatment of hepatitis B.

Conclusion

Yangtao Wu's innovative research and patent contributions in the field of hepatitis B are paving the way for new therapeutic approaches. His work exemplifies the importance of scientific innovation in addressing global health challenges.